Vanda Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Vanda Pharmaceuticals (VNDA).

Price Target Range — 10 Quarters

Analyst Consensus — 6 Analysts

5Buy

1Hold

Consensus RatingBuy# Analysts6Avg. Consensus PT$13Upside to Avg. PT+218.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 5, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$20
Sep 23, 2026	Oppenheimer	Les Sulewski	Initiate	Outperform	$10
Aug 10, 2026	B. Riley Securities	Madison El-Saadi	PT Cut	Buy	$17→$12
Aug 10, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$21→$20
May 11, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$24→$21
Mar 5, 2026	Truist Securities	Les Sulewski	Initiate	Buy	$18
Feb 23, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$22→$24
Jan 5, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$20→$22
Dec 31, 2025	B. Riley Securities	Madison El-Saadi	PT Raise	Buy	$11→$14
Dec 31, 2025	Jefferies	Chris Howerton	PT Raise	Hold	$5→$8
Nov 19, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$20
Nov 5, 2025	B. Riley Securities	Madison El-Saadi	Initiate	Buy	$11
Oct 30, 2025	Cantor Fitzgerald	Olivia Brayer	PT Cut	Overweight	$13→$11
Aug 21, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$20
May 14, 2025	Cantor Fitzgerald	Olivia Brayer	Assumes	Overweight	$13
May 7, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$20
Apr 1, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$20
Feb 18, 2025	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$18→$20
Feb 4, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$18
Jan 28, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$18

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Vanda Pharmaceuticals, Maintains $20 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and maintains $20 price target.

Benzinga Newsdesk

PRO
Oppenheimer Initiates Coverage On Vanda Pharmaceuticals with Outperform Rating, Announces Price Target of $10

Oppenheimer analyst Les Sulewski initiates coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) with a Outperform rating and announces Price Target of $10.

Benzinga Newsdesk

PRO
B. Riley Securities Reiterates Buy on Vanda Pharmaceuticals, Lowers Price Target to $12

B. Riley Securities analyst Madison El-Saadi reiterates Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and lowers the price target from $17 to $12.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Vanda Pharmaceuticals, Lowers Price Target to $20

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and lowers the price target from $21 to $20.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Vanda Pharmaceuticals, Lowers Price Target to $21

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and lowers the price target from $24 to $21.

Benzinga Newsdesk

This Equinix Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Top Wall Street analysts changed outlook on top names. See analyst ratings page for full view. EQIX stock initiated with Outperform rating.

Avi Kapoor

Vanda Pharmaceuticals Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Vanda Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Vanda Pharmaceuticals, Maintains $20 Price Target

PRO
Oppenheimer Initiates Coverage On Vanda Pharmaceuticals with Outperform Rating, Announces Price Target of $10

PRO
B. Riley Securities Reiterates Buy on Vanda Pharmaceuticals, Lowers Price Target to $12

PRO
HC Wainwright & Co. Maintains Buy on Vanda Pharmaceuticals, Lowers Price Target to $20

PRO
HC Wainwright & Co. Maintains Buy on Vanda Pharmaceuticals, Lowers Price Target to $21

This Equinix Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

People Also Watch

People Also Watch

Vanda Pharmaceuticals Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Vanda Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Vanda Pharmaceuticals, Maintains $20 Price Target

PROOppenheimer Initiates Coverage On Vanda Pharmaceuticals with Outperform Rating, Announces Price Target of $10

PROB. Riley Securities Reiterates Buy on Vanda Pharmaceuticals, Lowers Price Target to $12

PROHC Wainwright & Co. Maintains Buy on Vanda Pharmaceuticals, Lowers Price Target to $20

PROHC Wainwright & Co. Maintains Buy on Vanda Pharmaceuticals, Lowers Price Target to $21

This Equinix Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Vanda Pharmaceuticals, Maintains $20 Price Target

PRO
Oppenheimer Initiates Coverage On Vanda Pharmaceuticals with Outperform Rating, Announces Price Target of $10

PRO
B. Riley Securities Reiterates Buy on Vanda Pharmaceuticals, Lowers Price Target to $12

PRO
HC Wainwright & Co. Maintains Buy on Vanda Pharmaceuticals, Lowers Price Target to $20

PRO
HC Wainwright & Co. Maintains Buy on Vanda Pharmaceuticals, Lowers Price Target to $21